InspireMD (NYSE:NSPR) PT Raised to $5.20

Posted by on Aug 9th, 2023

InspireMD (NYSE:NSPR – Get Free Report) had its target price lifted by analysts at Alliance Global Partners from $4.75 to $5.20 in a note issued to investors on Wednesday, FlyOnTheWall reports. Alliance Global Partners’ target price would suggest a potential upside of 67.74% from the stock’s previous close.

NSPR has been the subject of a number of other reports. Piper Sandler began coverage on InspireMD in a report on Monday, June 12th. They issued an “overweight” rating for the company. StockNews.com assumed coverage on InspireMD in a report on Thursday, July 27th. They issued a “sell” rating for the company.

Get Our Latest Research Report on InspireMD

InspireMD Stock Performance

Shares of NYSE:NSPR opened at $3.10 on Wednesday. InspireMD has a one year low of $0.81 and a one year high of $3.74. The business’s 50-day simple moving average is $2.54 and its 200 day simple moving average is $1.70. The company has a market cap of $65.69 million, a P/E ratio of -1.35 and a beta of 1.01.

InspireMD (NYSE:NSPR – Get Free Report) last posted its quarterly earnings data on Monday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter. InspireMD had a negative return on equity of 93.16% and a negative net margin of 349.45%. The business had revenue of $1.24 million for the quarter. Analysts predict that InspireMD will post -1.11 earnings per share for the current year.

Insider Activity at InspireMD

In related news, Director Paul Stuka acquired 175,000 shares of InspireMD stock in a transaction that occurred on Friday, May 12th. The stock was acquired at an average price of $1.63 per share, for a total transaction of $285,250.00. Following the transaction, the director now directly owns 248,534 shares of the company’s stock, valued at approximately $405,110.42. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 21.62% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in InspireMD stock. Nottingham Advisors Inc. purchased a new position in shares of InspireMD, Inc. (NYSE:NSPR – Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 25,000 shares of the company’s stock, valued at approximately $63,000. Nottingham Advisors Inc. owned 0.12% of InspireMD as of its most recent filing with the Securities and Exchange Commission. 1.34% of the stock is owned by hedge funds and other institutional investors.

About InspireMD

(Get Free Report)

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Delivery System, a mesh-covered self-expanding carotid stent; SwitchGuard, a non-invasive transcarotid artery revascularization device; and NGuard EPS for treating acute stroke with tandem lesions.

Featured Stories

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.